182 related articles for article (PubMed ID: 8878573)
1. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
Djurković-Djaković O; Nikolić T; Robert-Gangneux F; Bobić B; Nikolić A
Antimicrob Agents Chemother; 1999 Sep; 43(9):2240-4. PubMed ID: 10471572
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Romand S; Bryskier A; Moutot M; Derouin F
J Antimicrob Chemother; 1995 Jun; 35(6):821-32. PubMed ID: 7559193
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Djurković-Djaković O; Milenković V; Nikolić A; Bobić B; Grujić J
J Antimicrob Chemother; 2002 Dec; 50(6):981-7. PubMed ID: 12461021
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Sordet F; Aumjaud Y; Fessi H; Derouin F
Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.
Moshkani SK; Dalimi A
Vet Res Commun; 2000 Apr; 24(3):169-77. PubMed ID: 10836275
[TBL] [Abstract][Full Text] [Related]
8. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I; Aleksić A
Microbes Infect; 2005 Jan; 7(1):49-54. PubMed ID: 15716077
[TBL] [Abstract][Full Text] [Related]
9. Rifabutin is active in murine models of toxoplasmosis.
Araujo FG; Slifer T; Remington JS
Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
[TBL] [Abstract][Full Text] [Related]
10. Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection.
Ferreira RA; Oliveira AB; Gualberto SA; Vitor RW
Parasite; 2002 Sep; 9(3):261-9. PubMed ID: 12375370
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
12. Rifapentine is active in vitro and in vivo against Toxoplasma gondii.
Araujo FG; Khan AA; Remington JS
Antimicrob Agents Chemother; 1996 Jun; 40(6):1335-7. PubMed ID: 8725996
[TBL] [Abstract][Full Text] [Related]
13. In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii.
Olliaro P; Gorini G; Jabes D; Regazzetti A; Rossi R; Marchetti A; Tinelli C; Della Bruna C
J Antimicrob Chemother; 1994 Nov; 34(5):649-57. PubMed ID: 7706160
[TBL] [Abstract][Full Text] [Related]
14. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo FG; Suzuki Y; Remington JS
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
[TBL] [Abstract][Full Text] [Related]
15. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Ferreira RA; Oliveira AB; Ribeiro MF; Tafuri WL; Vitor RW
Exp Parasitol; 2006 Jun; 113(2):125-9. PubMed ID: 16458300
[TBL] [Abstract][Full Text] [Related]
16. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
17. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O
Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624
[TBL] [Abstract][Full Text] [Related]
18. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.
Araujo FG; Huskinson J; Remington JS
Antimicrob Agents Chemother; 1991 Feb; 35(2):293-9. PubMed ID: 2024964
[TBL] [Abstract][Full Text] [Related]
19. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
Khan AA; Lambert LH; Remington JS; Araujo FG
Antimicrob Agents Chemother; 1999 Apr; 43(4):758-62. PubMed ID: 10103177
[TBL] [Abstract][Full Text] [Related]
20. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.
Khan AA; Slifer T; Araujo FG; Polzer RJ; Remington JS
Antimicrob Agents Chemother; 1997 May; 41(5):893-7. PubMed ID: 9145840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]